After a very large three year gain in uniQure's share price, the stock now screens as overvalued on market multiples and carries a mixed overall value score rather than a clear bargain signal. The recent run and the current valuation checks give investors a more finely balanced picture.

• Over the past three years, uniQure has returned very close to 7x for shareholders, which places extra focus on how much of the company's future potential is already priced in.

• The recent Biologics License Application for ifezuntirgene inilparvovec in Huntington's disease can support higher growth expectations if regulators respond positively. Any delays or setbacks in this program may weigh heavily on the valuation given how central it is to the story.

• With a value score of 3 , uniQure shows a mixed picture rather than a clear bargain or clear overvaluation across the broader set of valuation checks.

The issue now is whether uniQure's current share price still offers enough potential return to justify the risks embedded in these expectations.

Broaden your watchlist beyond uniQure by scanning hand picked gene therapy and biotech peers with resilient balance sheets and cash flows in the solid balance sheet and fundamentals stocks screener (52 results) .

Has uniQure Run Too Far on Book Value?

P/B is a useful cross check for uniQure because the stock is still in a loss making phase and earnings based multiples are less informative. It gives you a simple view of how much investors are paying for each dollar of net assets on the balance sheet.

uniQure trades at a P/B of about 9.9x, which is well above the broader Biotechs industry average of 2.5x and slightly below the peer group average of 10.9x. Despite the recent Biologics License Application for ifezuntirgene inilparvovec lifting interest in the story, this still leaves the stock priced on a rich multiple of its book value compared with the wider sector.

On this metric, investors are paying a substantial premium to the typical biotech company for exposure to uniQure's asset base, including its gene therapy platform and pipeline.

On a pure P/B comparison, uniQure appears expensive relative to the wider biotech industry.

See what the numbers say about this price — find out in our valuation breakdown.

The uniQure Narrative: What Would Justify Today's Price?

Simply Wall St Narratives pick up where the uniQure valuation puzzle leaves off. They outline which combinations of future growth, margins and earnings would need to hold for uniQure's stock to be worth materially more or less than today's price, using each narrative as a clear thesis about the business that you can revisit over time to see how well it fits the unfolding story. These are available on Simply Wall St's Community page.